# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-over-300-gains-say-analysts/
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker change...
HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pric...
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate...
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...